Combined Chemo- and Photothermal Therapies of Non-Small Cell Lung Cancer Using Polydopamine/Au Hollow Nanospheres Loaded with Doxorubicin

被引:3
|
作者
Zhang, Xinbo [1 ]
Xu, Bin [1 ]
Ni, Jiangwei [1 ]
Xiang, Yucheng [1 ]
He, Zhifeng [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Wenzhou, Zhejiang, Peoples R China
来源
关键词
non-small cell lung cancer; chemotherapy; photothermal therapy; doxorubicin; Au nanoparticles; NANOPARTICLES; ATLANTIS;
D O I
10.2147/IJN.S473137
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Purpose: The chemotherapeutic agent doxorubicin (DOX) is limited by its cardiotoxicity, posing challenges in its application for nonsmall cell lung cancer (NSCLC). This study aims to explore the efficacy of polydopamine/Au nanoparticles loaded with DOX for chemotherapy and photothermal therapy in NSCLC to achieve enhanced efficacy and reduced toxicity. Methods: Hollow polydopamine (HPDA)/Au@DOX was synthesized via polydopamine chemical binding sacrificial template method. Morphology was characterized using transmission electron microscopy, particle size and potential were determined using dynamic light scattering, and photothermal conversion efficiency was assessed using near-infrared (NIR) thermal imaging. Drug loading rate and in vitro drug release were investigated. In vitro, anti-tumor experiments were conducted using CCK-8 assay, flow cytometry, and live/dead cell staining to evaluate the cytotoxicity of HPDA/Au@DOX on A549 cells. Uptake of HPDA/Au@DOX by A549 cells was detected using the intrinsic fluorescence of DOX. The in vivo anti-metastasis and anti-tumor effects of HPDA/ Au@DOX were explored in mouse lung metastasis and subcutaneous tumor models, respectively. Results: HPDA/Au@DOX with a particle size of (164.26 +/- 3.25) nm, a drug loading rate of 36.31%, and an encapsulation efficiency of 90.78% was successfully prepared. Under 808 nm laser irradiation, HPDA/Au@DOX accelerated DOX release and enhanced uptake by A549 cells. In vitro photothermal performance assessment showed excellent photothermal conversion capability and stability of HPDA/Au@DOX under NIR laser irradiation. Both in vitro and in vivo experiments demonstrated that the photothermalchemotherapy combination group (HPDA/Au@DOX+NIR) exhibited stronger anti-metastatic and anti-tumor activities compared to the monotherapy group (DOX). Conclusion: HPDA/Au@DOX nanosystem demonstrated excellent photothermal effect, inhibiting the growth and metastasis of A549 cells. This nanosystem achieves the combined effect of chemotherapy and photothermal, making it promising for NSCLC treatment.
引用
收藏
页码:9597 / 9612
页数:16
相关论文
共 50 条
  • [1] Pneumonectomy after chemo- or chemoradiotherapy for advanced non-small cell lung cancer
    Collaud, S.
    Krbek, T.
    Hillinger, S.
    Fechner, S.
    Kestenholz, P.
    Stahel, R.
    Stamatis, G.
    Weder, W.
    SWISS MEDICAL WEEKLY, 2009, 139 (13-14) : 6S - 6S
  • [2] Au Nanoclusters Embedded in Polydopamine for Photothermal Radiotherapy on Non-Small-Cell Lung Cancer
    Hu, Ping
    Tian, Xiufen
    Sun, Zhiyu
    Yu, Xiaojun
    Wei, Xuguo
    Jiang, Hechun
    Wang, Xiali
    Yang, Dawei
    Jiang, Xiaohong
    ACS APPLIED NANO MATERIALS, 2024, 7 (16) : 19724 - 19736
  • [3] Radiotherapy for oligoprogression in metastatic non-small cell lung cancer patients receiving (chemo-)immunotherapy
    Deng, M.
    Bozorgmehr, F.
    Weykamp, F.
    Lang, K.
    Regnery, S.
    Held, T.
    Weusthof, K.
    Bauer, L.
    Waldsperger, H.
    Shafie, R. E.
    Rieken, S.
    Christopoulos, P.
    Thomas, M.
    Debus, J. Peter
    Adeberg, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S105 - S105
  • [4] Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model
    Changran Geng
    Harald Paganetti
    Clemens Grassberger
    Scientific Reports, 7
  • [5] Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model
    Geng, Changran
    Paganetti, Harald
    Grassberger, Clemens
    SCIENTIFIC REPORTS, 2017, 7
  • [6] Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone, Tina
    Gridelli, Cesare
    Ciardiello, Fortunato
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) : 98 - 102
  • [7] NONSURGICAL COMBINED MODALITY THERAPIES IN NON-SMALL CELL LUNG-CANCER
    KLASTERSKY, J
    SCULIER, JP
    CHEST, 1986, 89 (04) : S289 - S294
  • [8] Targeted therapies for non-small cell lung cancer
    Papaetis, G. S.
    Roussos, C.
    Syrigos, K. N.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) : 2810 - 2831
  • [9] Maintenance therapies for non-small cell lung cancer
    Blais, Normand
    Kassouf, Elie
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [10] Novel Therapies for Non-Small Cell Lung Cancer
    Donington, Jessica S.
    Koo, Chi Wan
    Ballas, Marc S.
    JOURNAL OF THORACIC IMAGING, 2011, 26 (02) : 175 - 185